Modality
Bispecific Ab
MOA
CAR-T BCMA
Target
BCL-2
Pathway
Proteasome
MCCAMLET
Development Pipeline
Preclinical
~May 2016
→ ~Aug 2017
Phase 1
Nov 2017
→ Feb 2028
Phase 1Current
NCT04223508
2,795 pts·MCC
2017-11→2028-02·Not yet recruiting
2,795 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-02-161.9y awayInterim· MCC
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1
Not yet…
Catalysts
Interim
2028-02-16 · 1.9y away
MCC
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04223508 | Phase 1 | MCC | Not yet recr... | 2795 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-4339 | Argenx | Phase 2 | BCL-2 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn |